Mariano Ponz-Sarvisé

30PUBLICATIONS
308CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSystems physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Oct 08, 2026
Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer.

|Jun 01, 2026
Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers.

|Mar 09, 2026
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

Changhoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Feb 26, 2026
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca

|Jan 16, 2026
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamon

Pageof 5

Frequent Collaborators

6 joint publications

Silvestre Vicent

3 joint publications

Ignacio Melero

3 joint publications

Teresa Macarulla Mercade

3 joint publications

Federico Longo